MyelomA genetics international consortium

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 796-800

  Morgan, Gareth ^a   Johnsen, Hans Erik ^b   Goldschmidt, Hartmut ^c   Palumbo, Antonio ^d   Cavo, Michele ^e   Sonneveld, Pieter ^f   Miguel, Jesus San ^g   Chim, Char Sang ^h   Browne, Paul ⁱ   Einsele, Hermann ^j   Waage, Anders ^k   Turesson, Ingemar ^l   Spencer, Andrew ^m   Hajek, Roman ⁿ   Ludwig, Heinz ^o   Hemminki, Kari ^p   Houlston, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF SALAMANCA   (Spain)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ ST JAMES S HOSPITAL   (Ireland)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m ALFRED HOSPITAL   (Australia)

ⁿ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^o WILHELMINEN HOSPITAL   (Austria)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

consortium; etiology; genetics; Multiple myeloma

Indexed keywords

BODY MASS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOTYPE; HAPLOTYPE; HUMAN; LIBRARY SCIENCE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INTERNATIONAL AGENCIES; MULTIPLE MYELOMA;

EID: 84859972113     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.639881     Document Type: Review

References (32)

1. K yle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873.
2. P alumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060.
3. B ecker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011;183:25-35.
4. A ltieri A, Chen B, Bermejo JL, et al. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006;42:1661-1670. (Pubitemid 44118762)
5. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569. (Pubitemid 34438817)
6. L andgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009;114:791-795.
7. Maggini V, Buda G, Galimberti S, et al. Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res 2008;32:988-990. (Pubitemid 351389549)
8. K ang SH, Kim TY, Kim HY, et al. Protective role of CYP1A1 2A in the development of multiple myeloma. Acta Haematol 2008;119:60-64. (Pubitemid 351363862)
9. Kang SH, Kim TY, Kim HY, et al. [Association of NQO1 Polymorphism with Multiple Myeloma Risk in Koreans]. Korean J Lab Med 2006;26:71-76.
10. Lima CS, Ortega MM, Ozelo MC, et al. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res 2008;32:401-405. (Pubitemid 351295908)
11. K im HN, Kim YK, Lee IK, et al. Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma. Am J Hematol 2007;82:798-801.
12. Lincz LF, Scorgie FE, Kerridge I, et al. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 2003;120:1051-1054. (Pubitemid 36411565)
13. Hosgood HD 3rd, Baris D, Zhang Y, et al. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 2009;33:1609-1614.
14. H osgood HD 3rd, Baris D, Zhang Y, et al. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008;26:148-151.
15. J amroziak K, Balcerczak E, Calka K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009;33:332-335.
16. B irmann BM, Tamimi RM, Giovannucci E, et al. Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009;18: 282-288.
17. A bazis-Stamboulieh D, Oikonomou P, Papadoulis N, et al. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007;48:2196-2203. (Pubitemid 350091062)
18. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442. (Pubitemid 38443646)
19. D udbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008;32:227-234. (Pubitemid 351550369)
20. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-1320.
21. P rice AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-909. (Pubitemid 44141658)
22. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10:353-361.
23. A bazis-Stamboulieh D, Oikonomou P, Papadoulis N, et al. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007;48:2196-2203. (Pubitemid 350091062)
24. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442. (Pubitemid 38443646)
25. D udbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008;32:227-234. (Pubitemid 351550369)
26. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-1320.
27. P rice AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-909. (Pubitemid 44141658)
28. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10:353-361.
29. J ones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446-449.
30. O lcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450-454.
31. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009;41:455-459.
32. Spencer CC, Su Z, Donnelly P, et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009;5:e1000477.